Research progress in delivery systems of mesenchymal stem cells carrying paclitaxel
10.7644/j.issn.1674-9960.2024.09.012
- VernacularTitle:运载紫杉醇的干细胞递送系统研究进展
- Author:
Yihao PEI
1
;
Siyao CHEN
;
Yuyin SU
;
Yiming MAO
;
Ben LI
Author Information
1. 锦州医科大学医疗学院口腔医学系,辽宁锦州 121000
- Keywords:
mesenchymal stem cells;
drug delivery systems;
paclitaxel;
targeted cancer therapy;
cancer biotherapy;
chemotherapy;
cell therapy
- From:
Military Medical Sciences
2024;48(9):708-714
- CountryChina
- Language:Chinese
-
Abstract:
Mesenchymal stem cells have emerged as a promising cell therapy for anti-tumor research due to their homing properties,low immunogenicity,anti-angiogenic activity,anti-inflammatory properties,and paracrine effects.Paclitaxel has been clinically used for over thirty years in the treatment of various tumors such as ovarian cancer,lung cancer,and breast cancer.However,the broad-spectrum anti-tumor properties of paclitaxel are not possessed by the aforementioned cell therapies.Moreover,its adverse reactions,including peripheral neuropathy,bone marrow suppression,and gastrointestinal reactions,have long plagued cancer patients.In recent years,many studies have focused on combining cell therapy with chemotherapy to achieve better treatment outcomes,giving rise to a new drug delivery system that utilizes mesenchymal stem cells as carriers for delivering chemotherapeutic drugs.This review summarizes the research progress in MSC-based drug delivery systems for paclitaxel.
